Aparajita Hoskote Chourasia, PhD
About Aparajita Hoskote Chourasia, PhD
Aparajita Hoskote Chourasia, M.S., Ph.D. at Biotheryx
Aparajita Hoskote Chourasia, M.S., Ph.D., serves as the Senior Vice President of Development and Biology at Biotheryx. Joining the company in 2017, she has ascended through various leadership roles, including Vice President of Biology in October 2021 and Vice President of Preclinical and Translational Biology in April 2023, before assuming her current position in January 2024. At Biotheryx, she leads the entire preclinical biology effort focused on developing targeted protein degraders.
Aparajita Hoskote Chourasia's Education and Expertise
Aparajita Hoskote Chourasia earned her Ph.D. in cancer biology from the University of Chicago, where she researched the tumor suppressive function of BNIP3 mediated mitochondrial autophagy in mammary and pancreatic tumorigenesis. She also holds an M.S. in biochemistry and molecular biology from the University of Illinois, Chicago, and an M.S. in translational science from Howard Hughes Medical Institute. Her academic background has provided her with extensive expertise in molecular pathways in cancer, tumor models, tumor metabolism, inflammation, and assay development.
Aparajita Hoskote Chourasia's Professional Background
Before joining Biotheryx, Aparajita Hoskote Chourasia worked at Veridex (a Johnson & Johnson company), Novartis Institutes for Biomedical Research, and the Brigham and Women Hospital, a teaching affiliate of Harvard Medical School. Throughout her career, she has accrued substantial expertise in various scientific areas, contributing significantly to drug discovery and development. Her work has included identifying targets, establishing assays, and developing intellectual property within the biotech industry.
Achievements of Aparajita Hoskote Chourasia
Aparajita Hoskote Chourasia has made significant contributions to the field of cancer biology and drug development. Her efforts at Biotheryx have been pivotal in advancing the development of targeted protein degraders. Additionally, she has secured successful NIH-funded research awards and authored peer-reviewed research articles and reviews, showcasing her impact and recognition in the scientific community.